Abstract
All-trans retinoic acid (atRA) is the transcriptionally active product of vitamin A and induces gene expression via specific receptors at nM concentrations. Essential enzymes that regulate the local levels of atRA are the CYP26 members of the cytochrome P450 family, which catabolize atRA. Compounds that have been designed to inhibit these enzymes are known as Retinoic Acid Metabolic Blocking Agents (RAMBAs). Treatment with these compounds will raise endogenous atRA levels and may be therapeutic for the treatment of diseases that respond to high atRA concentrations, including several types of cancer as well as skin conditions such as psoriasis and acne. This review describes the mechanism of action of the RAMBAs and discusses the potential side effects of these compounds. atRA is highly teratogenic and the potential teratogenicity of the RAMBAs is described by comparison with the abnormalities resulting from null mutation of individual CYP26 genes. The possible effects of RAMBAs on the adult brain are also described that have the potential for harm but, in the right circumstances, may also be beneficial.
Keywords: Retinoic acid, CYP26, catabolism, caudal regression, limb defect, neurogenesis, hippocampus
Current Pharmaceutical Design
Title: Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Volume: 13 Issue: 29
Author(s): P. McCaffery and C. Simons
Affiliation:
Keywords: Retinoic acid, CYP26, catabolism, caudal regression, limb defect, neurogenesis, hippocampus
Abstract: All-trans retinoic acid (atRA) is the transcriptionally active product of vitamin A and induces gene expression via specific receptors at nM concentrations. Essential enzymes that regulate the local levels of atRA are the CYP26 members of the cytochrome P450 family, which catabolize atRA. Compounds that have been designed to inhibit these enzymes are known as Retinoic Acid Metabolic Blocking Agents (RAMBAs). Treatment with these compounds will raise endogenous atRA levels and may be therapeutic for the treatment of diseases that respond to high atRA concentrations, including several types of cancer as well as skin conditions such as psoriasis and acne. This review describes the mechanism of action of the RAMBAs and discusses the potential side effects of these compounds. atRA is highly teratogenic and the potential teratogenicity of the RAMBAs is described by comparison with the abnormalities resulting from null mutation of individual CYP26 genes. The possible effects of RAMBAs on the adult brain are also described that have the potential for harm but, in the right circumstances, may also be beneficial.
Export Options
About this article
Cite this article as:
McCaffery P. and Simons C., Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity, Current Pharmaceutical Design 2007; 13 (29) . https://dx.doi.org/10.2174/138161207782110534
DOI https://dx.doi.org/10.2174/138161207782110534 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of the Current Role of Proton Therapy in Modern Oncology
Current Drug Therapy Strategies to Direct Angiogenesis within Scaffolds for Bone Tissue Engineering
Current Pharmaceutical Design Application of Quantum Dots in Drug Delivery
Nanoscience & Nanotechnology-Asia The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer
Current Cancer Drug Targets Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Viral Carcinogenesis of Oral Region and Recent Trends in Treatment
Recent Patents on Biomarkers MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Descending Necrotizing Mediastinitis of Odontogenic Origin
Recent Patents on Anti-Infective Drug Discovery 3D-QSAR Studies of Natural Steroidal Saponins as Anticancer Agents in Human Nasopharyngeal Carcinoma Epithelial Cells
Letters in Drug Design & Discovery Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression
Current Molecular Medicine Socioeconomic Consequences of Cervical Cancer: A Narrative Review
Current Women`s Health Reviews Intracellular Fate of Peptide-Mediated Delivered Cargoes
Current Pharmaceutical Design Dibenzoylmethane Activates Nrf2-Dependent Detoxification Pathway and Inhibits Benzo(a)pyrene Induced DNA Adducts in Lungs
Medicinal Chemistry Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry Transmission and Immunopathogenesis of FIV in Cats as a Model for HIV
Current HIV Research Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
Anti-Cancer Agents in Medicinal Chemistry Drug Delivery Systems for Prevention and Treatment of Osteoporotic Fracture
Current Drug Targets Elucidating Molecular Interactions of Ten Natural Compounds Targeting E6 HPV High Risk Oncoproteins Using Microsecond Molecular Dynamics Simulations
Medicinal Chemistry Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model
Anti-Cancer Agents in Medicinal Chemistry